Patents by Inventor Tariq Ghayur

Tariq Ghayur has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF
    Publication number: 20160319026
    Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.
    Type: Application
    Filed: April 5, 2016
    Publication date: November 3, 2016
    Inventors: Tariq Ghayur, Junjian Liu, Gillian A. Kingsbury, Edward B. Reilly, Susan E. Morgan-Lappe, Jijie Gu
  • GLYCOENGINEERED BINDING PROTEIN COMPOSITIONS
    Publication number: 20160319010
    Abstract: Provided are glycoengineered populations of Fc domain-containing binding proteins with a reduced anti-drug immune response (ADA). Also provided are methods of treating disease using such compositions, and methods and host for making such compositions.
    Type: Application
    Filed: June 30, 2016
    Publication date: November 3, 2016
    Inventors: Boris Labkovsky, Tariq Ghayur, Georgeen Gaza-Bulseco, Pratibha Mishra, Subramanya Hegde, Sudha Krishnan
  • DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF
    Publication number: 20160280791
    Abstract: Engineered multivalent and multispecific binding proteins that bind two different (e.g., nonoverlapping) epitopes of the same receptor or two different receptors expressed on the same cell are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease.
    Type: Application
    Filed: March 21, 2016
    Publication date: September 29, 2016
    Applicant: AbbVie Inc.
    Inventors: Tariq Ghayur, Jijie Gu, Carrie L. Goodreau
  • TNF-ALPHA BINDING PROTEINS
    Publication number: 20160272703
    Abstract: TNF-? binding proteins, including chimeric, CDR-grafted, and humanized antibodies that bind TNF-? are provided. Binding proteins have high affinity for TNF-? and neutralize TNF-? activity. A binding protein can be a full-length antibody or a TNF-?-binding portion thereof. Methods of making and methods of using the binding proteins are also described. The TNF-? binding proteins are useful for detecting TNF-? and for inhibiting TNF-? activity, including in a human subject suffering from a disease or disorder in which TNF-? activity is detrimental.
    Type: Application
    Filed: February 15, 2016
    Publication date: September 22, 2016
    Inventors: Chung-ming HSIEH, Carrie GOODREAU, Tariq GHAYUR, Achim MOELLER, Sahana BOSE
  • IL-1 binding proteins
    Patent number: 9447183
    Abstract: Proteins that bind IL-1? and IL-1? are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-1-related disorders and for detecting IL-1? and IL-1? in cells, tissues, samples, and compositions.
    Type: Grant
    Filed: December 16, 2013
    Date of Patent: September 20, 2016
    Assignee: AbbVie Inc.
    Inventors: Chengbin Wu, Dominic J. Ambrosi, Chung-ming Hsieh, Tariq Ghayur
  • IL-1 binding proteins
    Patent number: 9447184
    Abstract: Proteins that bind IL-1? and IL-1? are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-1-related disorders and for detecting IL-1? and IL-1? in cells, tissues, samples, and compositions.
    Type: Grant
    Filed: December 26, 2013
    Date of Patent: September 20, 2016
    Assignee: AbbVie Inc.
    Inventors: Chengbin Wu, Dominic J. Ambrosi, Chung-ming Hsieh, Tariq Ghayur
  • IL-1 binding proteins
    Patent number: 9441038
    Abstract: Proteins that bind IL-1? and IL-1? are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-1-related disorders and for detecting IL-1? and IL-1? in cells, tissues, samples, and compositions.
    Type: Grant
    Filed: December 17, 2013
    Date of Patent: September 13, 2016
    Assignee: AbbVie Inc.
    Inventors: Chengbin Wu, Dominic J. Ambrosi, Chung-ming Hsieh, Tariq Ghayur
  • METHODS OF TREATMENT USING SELECTIVE BCL-2 INHIBITORS
    Publication number: 20160235760
    Abstract: This invention pertains to methods of treating systemic lupus erythematosus and Sjogren's Syndrome with compounds that selectively inhibit the activity of Bcl-2 anti-apoptotic proteins.
    Type: Application
    Filed: April 22, 2016
    Publication date: August 18, 2016
    Inventors: Steven Elmore, Andrew Souers, Lichun Wang, Tariq Ghayur, Stuart J. Perper
  • IL-1 binding proteins
    Patent number: 9409986
    Abstract: Proteins that bind IL-1? and IL-1? are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-1-related disorders and for detecting IL-1? and IL-1? in cells, tissues, samples, and compositions.
    Type: Grant
    Filed: December 18, 2013
    Date of Patent: August 9, 2016
    Assignee: AbbVie Inc.
    Inventors: Chengbin Wu, Dominic J. Ambrosi, Chung-ming Hsieh, Tariq Ghayur
  • METHOD OF PREVENTING OR TREATING ORGAN, HEMATOPOIETIC STEM CELL OR BONE MARROW TRANSPLANT REJECTION
    Publication number: 20160175316
    Abstract: Methods of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection are disclosed.
    Type: Application
    Filed: December 17, 2015
    Publication date: June 23, 2016
    Inventors: Philip Bardwell, Tariq Ghayur, Jijie Gu, Ingela Beatrice Vikstrom, Andrew Mark Lew, David Matthew Tarlinton, Emma Margarele Carrington, David Ching Siang Huang
  • TNF-ALPHA BINDING PROTEINS
    Publication number: 20160176958
    Abstract: Isolated binding proteins, e.g., antibodies or antigen binding portions thereof, which bind to tumor necrosis factor-alpha (TNF-?), e.g., human TNF-?, and related antibody-based compositions and molecules are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, as well as therapeutic and diagnostic methods for using the antibodies.
    Type: Application
    Filed: November 24, 2015
    Publication date: June 23, 2016
    Inventors: Lorenzo Benatuil, Tariq Ghayur, Carrie L. Goodreau, Peter C. Isakson, Jochen Salfeld
  • NEUTRALIZING MONOCLONAL ANTIBODIES AGAINST THE NOGO-66 RECEPTOR (NgR) AND USES THEREOF
    Publication number: 20160145334
    Abstract: The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind to the Nogo-66 receptor. Specifically, these antibodies have the ability to inhibit the binding of the natural ligand of the Nogo-66 receptor and neutralize the Nogo-66 receptor. These antibodies or portions thereof of the invention are useful for detecting NgR and for inhibiting NgR activity, for example in a human suffering from a disorder in which NgR or Nogo-66 activity is detrimental.
    Type: Application
    Filed: January 6, 2016
    Publication date: May 26, 2016
    Inventors: Mario Mezler, Achim Moeller, Reinhold Mueller, Bernhard K. Mueller, Tariq Ghayur, Eve H. Barlow, Martin Schmidt, Axel Meyer, Nicole Teusch
  • Methods of treatment using selective Bcl-2 inhibitors
    Patent number: 9345702
    Abstract: This invention pertains to methods of treating systemic lupus erythematosus and Sjogren's Syndrome with compounds that selectively inhibit the activity of Bcl-2 anti-apoptotic proteins. Specifically, the current invention is directed to treatment with compounds that selectively inhibit the activity of Bcl-2 proteins, with a lesser affinity for inhibiting the activity of other BCL-2 family proteins, including Bcl-xL.
    Type: Grant
    Filed: November 6, 2014
    Date of Patent: May 24, 2016
    Assignee: AbbVie Inc.
    Inventors: Steven Elmore, Andrew Souers, Lichun Wang, Tariq Ghayur, Stuart J. Perper
  • METHOD OF TREATING ARTHRITIS
    Publication number: 20160101109
    Abstract: Methods of preventing or treating arthritis is disclosed.
    Type: Application
    Filed: December 17, 2015
    Publication date: April 14, 2016
    Inventors: Philip Bardwell, Tariq Ghayur
  • IL-1 binding proteins
    Patent number: 9303085
    Abstract: Proteins that bind IL-1? and IL-1? are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-1-related disorders and for detecting IL-1? and IL-1? in cells, tissues, samples, and compositions.
    Type: Grant
    Filed: December 12, 2013
    Date of Patent: April 5, 2016
    Assignee: ABBVIE INC.
    Inventors: Chengbin Wu, Dominic J. Ambrosi, Chung-ming Hsieh, Tariq Ghayur
  • DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF
    Publication number: 20160046730
    Abstract: Engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease are provided.
    Type: Application
    Filed: July 29, 2015
    Publication date: February 18, 2016
    Inventors: Tariq Ghayur, Junjian Liu
  • Neutralizing monoclonal antibodies against the Nogo-66 receptor (NgR) and uses thereof
    Patent number: 9255146
    Abstract: The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind to the Nogo-66 receptor. Specifically, these antibodies have the ability to inhibit the binding of the natural ligand of the Nogo-66 receptor and neutralize the Nogo-66 receptor. These antibodies or portions thereof of the invention are useful for detecting NgR and for inhibiting NgR activity, for example in a human suffering from a disorder in which NgR or Nogo-66 activity is detrimental.
    Type: Grant
    Filed: August 29, 2013
    Date of Patent: February 9, 2016
    Assignees: ABBVIE INC., ABBVIE DEUTSCHLAND GMBH & CO. KG
    Inventors: Mario Mezler, Achim Moeller, Reinhold Mueller, Bernhard K. Mueller, Tariq Ghayur, Eve H. Barlow, Martin Schmidt, Axel Meyer, Nicole Teusch
  • BLOOD-BRAIN-BARRIER DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF
    Publication number: 20160032000
    Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.
    Type: Application
    Filed: May 22, 2015
    Publication date: February 4, 2016
    Inventors: Tariq Ghayur, Alfred Hahn, Bernhard Mueller
  • TNF-? binding proteins
    Patent number: 9226983
    Abstract: Isolated binding proteins, e.g., antibodies or antigen binding portions thereof, which bind to tumor necrosis factor-alpha (TNF-?), e.g., human TNF-?, and related antibody-based compositions and molecules are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, as well as therapeutic and diagnostic methods for using the antibodies.
    Type: Grant
    Filed: April 6, 2011
    Date of Patent: January 5, 2016
    Assignee: AbbVie Inc.
    Inventors: Lorenzo Benatuil, Tariq Ghayur, Carrie L. Goodreau, Peter C. Isakson, Jochen Salfeld
  • DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-13 AND/OR IL-17
    Publication number: 20150344566
    Abstract: Engineered multivalent and multispecific binding proteins that bind IL-13 and/or IL-17 are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease.
    Type: Application
    Filed: July 21, 2015
    Publication date: December 3, 2015
    Inventors: Chung-Ming HSIEH, Tariq GHAYUR, Carrie L. GOODREAU